-Iverson Genetics is currently conducting a five year, multi-center, nationwide study in collaboration with the Centers for Medicare and Medicaid Services (CMS), to assess the effectiveness of genetic testing in reducing the incidence of adverse events associated with the initiation of WARFARIN therapy. The WARFARIN Study Principal Investigator, An Pang Chieng, MD, will present “The Power of Companion Diagnostic Testing in Personalized Medicine” at this year’s Personalized Medicine World Conference. Dr. Chieng will outline the validated roadmap for study completion (expected 2015); and highlight the potential impact of pharmacogenetics on the future of healthcare and WARFARIN dosing safety / efficacy specifically.
Help employers find you! Check out all the jobs and post your resume.
